The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 25, 2020

Filed:

Sep. 27, 2017
Applicants:

The Board of Trustees of the University of Illinois, Urbana, IL (US);

Zimitech, Berkeley, CA (US);

Inventors:

Yong-Su Jin, Champaign, IL (US);

Jingjing Liu, Urbana, IL (US);

Kulika Chomvong, Berkeley, CA (US);

Jamie H. D. Cate, Berkeley, CA (US);

Guochang Zhang, Urbana, IL (US);

Assignees:

THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS, Urbana, IL (US);

ZIMITECH, Berkeley, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 1/20 (2006.01); C12R 1/865 (2006.01); C12N 1/16 (2006.01); C12N 15/52 (2006.01); C12P 19/02 (2006.01); C12N 9/40 (2006.01);
U.S. Cl.
CPC ...
C12R 1/865 (2013.01); C12N 1/16 (2013.01); C12N 9/2465 (2013.01); C12N 15/52 (2013.01); C12P 19/02 (2013.01); C12N 2330/50 (2013.01); C12N 2510/02 (2013.01); C12N 2511/00 (2013.01);
Abstract

The present disclosure provides genetically engineered microorganisms for tagatose production comprising one or more heterologous polynucleotides encoding polypeptides selected from cellodextrin transporter (Cdt-1), intracellular β-glucosidase (Gh1-1), xylose reductase (XR), galactitol 2-dehydrogenase (Gdh) and an AraA polypeptide, wherein any biological activity of endogenous Gal1 is attenuated or eliminated. Also provided are genetically engineered microorganism for psicose production comprising one or more heterologous polynucleotides encoding polypeptides selected from alpha-glucoside permease (Agt1) and psicose epimerase (Dpe), wherein any biological activity of endogenous sucrose invertase (Suc2), hexose kinase 1 (Hxk1), hexose kinase 2 (Hxk2), or combinations thereof are attenuated or eliminated. Methods of converting lactose to tagatose and sucrose to psicose is also provided.


Find Patent Forward Citations

Loading…